News | Antiplatelet and Anticoagulation Therapies | December 12, 2019

Low-dose Aspirin May Not Help African Americans Prevent Heart Disease

An observational study published in the Journal of the American Heart Association showed that low-dose aspirin appeared not to reduce the risk of a fatal heart attack, even when the analysis was restricted to people at the highest risk of cardiovascular disease

aspirin bottle

December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Americans, according to an observational study published in the Journal of the American Heart Association, the open access journal of the American Heart Association.

“Most available data shows that African Americans have a higher risk of having a heart attack, stroke or other heart diseases compared to whites; however, previous studies didn’t include enough black participants to determine if taking a low-dose aspirin for primary prevention of heart disease was useful for this group of people,” said Rodrigo Fernandez-Jimenez, M.D., Ph.D., the lead author of the study and a cardiologist and researcher at Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid, Spain, and former researcher at the Icahn School of Medicine at Mount Sinai in New York.

Results of the 11-year follow-up study showed that low-dose aspirin appeared not to reduce the risk of a fatal heart attack among African American participants, even when the analysis was restricted to people at the highest risk of cardiovascular disease (10-year cardiovascular risk greater than 10 percent according to the Framingham Risk Score). The study did show an association of low-dose aspirin with a trend toward decreased risk of fatal heart attacks in whites, particularly among women.

Researchers used data from the Southern Community Cohort Study, an ongoing initiative coordinated by Vanderbilt University that is tracking the risk factors for cancer and other major diseases of more than 65,000 predominantly low-income men and women, ages 40 to 79, who live in the Southeastern United States. More than two-thirds of the study participants are African American and approximately two-thirds of the participants were at high risk of having a heart attack or stroke at the start of the study, according to the Framingham Risk Score.

“We think the reason aspirin use did not have a beneficial effect for African Americans could involve a different genetic response to aspirin therapy and poor control of other risk factors,” Fernandez-Jimenez said. “The need to better understand the association between aspirin use, race/ethnicity and socioeconomic status and how these factors play a role in cardiovascular disease are important in light of these findings.” This was an observational study, not designed to prove cause and effect.

The American Heart Association does not recommend taking an aspirin to prevent cardiovascular disease without talking with a health care provider. If a person is at low risk for having a heart attack or stroke according to the American Heart Association/American College of Cardiology Atherosclerotic Cardiovascular Disease Risk Calculator, aspirin therapy is generally not advised for everyone because the possible benefits do not offset the risk of increased bleeding. Aspirin therapy may be appropriate for some people who are at higher risk of cardiovascular disease, however, decisions about aspirin use must be individualized to a patient’s specific health status in consultation with their physician.

Co-authors are Thomas J. Wang, M.D.; Valentin Fuster, M.D., Ph.D.; and William J. Blot, Ph.D. The authors reported no disclosures. The National Cancer Institute (NCI) at the National Institutes of Health and the American Heart Association supported the study.

For more information: www.heart.org

Related Content

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.